Hims & Hers Health, Inc.: insider trades · United States · SEC (Form 4)

About Hims & Hers Health, Inc.

Hims & Hers Health, Inc. (NYSE: HIMS) is a US-listed consumer health and telehealth platform headquartered in San Francisco, California, in the United States. Founded in 2017 by Andrew Dudum, Hilary Coles, Jack Abraham, and Joe Spector at the venture studio Atomic, the company was built around a direct-to-consumer model aimed at making healthcare more convenient, more accessible, and more personalized. From its early roots as a digitally native brand, Hims & Hers has evolved into a multi-specialty care platform that connects customers with licensed healthcare professionals and a broader set of health and wellness products and services. ([investors.hims.com](https://investors.hims.com/news/news-details/2021/Hims--Hers-Appoints-Two-New-Board-Members/default.aspx?utm_source=openai)) The company’s core business spans several consumer healthcare categories, including sexual health, dermatology, mental health, hair loss, primary care, heart health, weight loss, and other wellness-related offerings. Its model combines telehealth consultations, clinician-led care pathways, prescription fulfillment where appropriate, and branded products delivered through a digital customer experience. This integrated approach is central to the company’s competitive positioning: Hims & Hers is not just a telehealth marketplace, but a brand-led care platform designed to improve engagement, adherence, and customer retention. Management has consistently emphasized personalization, simplicity, and affordability as key differentiators in a crowded and evolving digital health market. ([investors.hims.com](https://investors.hims.com/news/news-details/2021/Hims--Hers-Appoints-Two-New-Board-Members/default.aspx?utm_source=openai)) Geographically, the company first established scale in the United States and reports service availability across all 50 states and Washington, D.C. It has recently moved beyond a purely domestic story and is pursuing an international growth strategy. In 2026, Hims & Hers announced an agreement to acquire Eucalyptus, a transaction intended to accelerate its ambition to become a leading global consumer health platform. That move signals a broader long-term opportunity beyond the US market, while also increasing execution and regulatory complexity. ([investors.hims.com](https://investors.hims.com/news/news-details/2021/Hims--Hers-Appoints-Two-New-Board-Members/default.aspx?utm_source=openai)) Recent developments have reinforced the company’s growth narrative. In May 2026, Hims & Hers reported first-quarter 2026 revenue of approximately $608 million, subscriber growth to nearly 2.6 million, and an upward revision to full-year 2026 guidance. The company has also continued to expand its product portfolio, including women’s health, weight-loss solutions, multi-cancer early detection testing, and partner-based wellness benefits. For investors, the equity case is therefore anchored in a combination of rapid top-line growth, product expansion, brand strength, and a scalable digital distribution model, alongside the usual telehealth sector risks related to regulation, clinical scrutiny, and competitive intensity. ([investors.hims.com](https://investors.hims.com/news/news-details/2026/Hims--Hers-Health-Inc--Reports-First-Quarter-2026-Financial-Results/default.aspx?utm_source=openai))